Home・Akciju saraksts・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Atvērts

SektorsVeselības aprūpe

6.42 0.16

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

6.3

Max

6.48

Galvenie mērījumi
By Trading Economics
Ienākumi	36M -3.7M
Pārdošana	16M 66M
EPS	0.01
Peļņas marža	-5.67
Darbinieki	416
EBITDA	54M 12M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-11.68% downside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.1B 2.5B
Iepriekšējā atvēršanas cena	6.26
Iepriekšējā slēgšanas cena	6.42

Ziņu noskaņojums

By Acuity

100%

320 / 340 Rangs Healthcare

Maravai LifeSciences Holdings Inc (Class A) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 19:46 UTC

Maravai LifeSciences Holdings Inc shares are lower during Monday's session, trading below their 20-day moving average with no specific news to explain the decline.

2026. g. 31. jūl. 19:36 UTC

Maravai LifeSciences Holdings Inc. shares are lower today amid broader market volatility, having previously dropped to a session low before partially recovering.

2026. g. 30. jūl. 16:56 UTC

Maravai LifeSciences Holdings Inc shares are gaining amid broader market recovery, with the S&P 500 advancing as investors engage in bargain hunting.

2026. g. 29. jūl. 20:09 UTC

Maravai LifeSciences Holdings Inc shares declined during Wednesday's session, pulling back from earlier gains amid broader market volatility and rising oil prices.

2026. g. 28. jūl. 18:06 UTC

Maravai LifeSciences Holdings Inc is gaining during Tuesday's session, though it pulled back from earlier highs amid broader market pressure in the tech sector.

2026. g. 24. jūl. 19:36 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market pressures, reflecting declines in the Nasdaq 100 following disappointing earnings from major tech companies.

2026. g. 23. jūl. 09:01 UTC

Maravai LifeSciences Holdings Inc. shares are lower in pre-market trading, continuing a decline since Wednesday's close without significant recovery.

2026. g. 22. jūl. 19:56 UTC

Maravai LifeSciences Holdings Inc. shares are lower today, retracing from earlier highs amid no specific company news. The stock remains above its 20-day moving average.

2026. g. 21. jūl. 19:56 UTC

News

Maravai LifeSciences' TriLink BioTechnologies secures a patent for CleanCap® technology in China, boosting confidence in RNA-based therapies. Shares are higher since Monday's close.

2026. g. 20. jūl. 20:02 UTC

Maravai LifeSciences Holdings Inc shares are lower amid broader market declines. The stock hit a session low earlier but has since recovered slightly.

Salīdzinājums

Cenas izmaiņa

Maravai LifeSciences Holdings Inc (Class A) Prognoze

Cenas mērķis

By TipRanks

-11.68% uz leju

Prognoze 12 mēnešiem

Vidējais 5.67 USD -11.68%

Augstākais 6 USD

Zemākais 5 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Maravai LifeSciences Holdings Inc (Class A) — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Maravai LifeSciences Holdings Inc (Class A) — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

320 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.